From the Department of Radiology (M.G.), University of Calgary, Alberta, Canada.
Department of Clinical Neurosciences (M.A.), University of Calgary, Alberta, Canada.
Stroke. 2019 Mar;50(3):645-651. doi: 10.1161/STROKEAHA.118.021840.
Background and Purpose- We report the relation of onset-to-treatment time and door-to-needle time with functional outcomes and mortality among patients with ischemic stroke with imaging-proven large vessel occlusion treated with intravenous alteplase. Methods- Individual patient-level data from the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration were pooled from 7 trials that randomized patients to mechanical thrombectomy added to best medical therapy versus best medical therapy alone. Analysis was restricted to patients who received alteplase directly at the endovascular hospital. The primary outcome was disability defined on the modified Rankin Scale at 3 months. Results- Among 601 patients, mean age was 66.0 years (SD, 13.9), 50% were women, and median National Institutes of Health Stroke Scale score was 17. Onset-to-treatment time was median 125 minutes (interquartile range, 90-170). Door-to-treatment time was median 38 minutes (interquartile range, 26-55). Each 60-minute onset-to-treatment time delay was associated with greater disability at 90 days; the odds of functional independence (modified Rankin Scale, 0-2) at 90 days was 0.82 (95% CI, 0.66-1.03). With each 60-minute delay in door-to-needle time; the odds of functional independence was 0.55 (95% CI, 0.37-0.81) at 90 days. The absolute decline in the rate of excellent outcome (modified Rankin Scale, 0-1 at 90 days) was 20.3 per 1000 patients treated per 15-minute delay in door-to-needle time. The adjusted absolute risk difference for a door-to-needle time <30 minutes versus 30 to 60 minutes was 19.3% for independent outcome (number-needed-to-treat ≈5 to gain 1 additional good outcome). Symptomatic intracranial hemorrhage occurred in 3.4% of patients, without a significant time dependency: odds ratio, 0.74 (95% CI, 0.43-1.28). Conclusions- Faster intravenous thrombolysis delivery is associated with less disability at 3 months among patients with large vessel occlusion.
背景与目的-我们报告了在接受静脉注射阿替普酶治疗的影像学证实的大血管闭塞性缺血性卒中患者中,发病至治疗时间和门到针时间与功能结局和死亡率的关系。方法-来自 HERMES(多血管内卒中介入试验中高度有效的再灌注评估)合作的 7 项随机试验的个体患者水平数据被汇总,这些试验将机械取栓术联合最佳药物治疗与单纯最佳药物治疗进行了比较。分析仅限于直接在血管内医院接受阿替普酶治疗的患者。主要结局是 3 个月时改良 Rankin 量表定义的残疾。结果-在 601 例患者中,平均年龄为 66.0 岁(标准差,13.9),50%为女性,美国国立卫生研究院卒中量表评分中位数为 17。发病至治疗时间中位数为 125 分钟(四分位距,90-170)。门到治疗时间中位数为 38 分钟(四分位距,26-55)。每 60 分钟的发病至治疗时间延迟与 90 天时的残疾程度增加相关;90 天时功能独立(改良 Rankin 量表,0-2)的可能性为 0.82(95%CI,0.66-1.03)。每延迟 60 分钟门到针时间,90 天时功能独立的可能性为 0.55(95%CI,0.37-0.81)。每延迟 15 分钟门到针时间,每 1000 例患者中,卓越结局(90 天时改良 Rankin 量表 0-1)的绝对下降率为 20.3。门到针时间<30 分钟与 30-60 分钟相比,调整后的绝对风险差异为 19.3%,用于独立结局(每治疗 5 例患者可获得 1 例额外的良好结局,所需人数≈5)。症状性颅内出血的发生率为 3.4%,且无明显的时间依赖性:比值比为 0.74(95%CI,0.43-1.28)。结论-大血管闭塞性缺血性卒中患者更快的静脉溶栓治疗与 3 个月时的残疾程度降低相关。